MedTrace Logo

Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

NCT05797740 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 367

Last updated 2026-05-22

No results posted yet for this study

Summary

This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other patient-reported, clinical, and imaging outcomes in participants with relapsing multiple sclerosis (RMS) in the long term, in a real-world setting.

Conditions

Interventions

DRUG

Mavenclad

This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.

Sponsors & Collaborators

  • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-03
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • Belgium
  • Czechia
  • Greece
  • Netherlands
  • Poland
  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05797740 on ClinicalTrials.gov